can you sue the NHS for improper prescribing of pregabalin

The short version: you can sue the NHS for improper pregabalin prescribing, but the legal bar is high and the evidence on what counts as "improper" is thin.

The NHS can be sued for clinical negligence, including improper prescribing. But the evidence here does not give you a clear standard for what "improper" means. The BMJ review [2] shows pregabalin works for some conditions (post-herpetic neuralgia, NNT 3.9) and barely works for others (diabetic neuropathy, NNT 7.8; fibromyalgia, NNT 11). For HIV neuropathy it was no better than placebo [2]. A Pfizer-funded safety analysis of 31 trials [16] found that 24% of patients on pregabalin reported dizziness, 15% somnolence, and 9% peripheral edema. The drug was reclassified as a Class C controlled substance in the UK in 2019 because deaths linked to misuse rose from 4 in 2012 to 136 in 2017 [3]. None of this tells you what a court would call improper.

The real problem is that the evidence base is funded by the manufacturer and built on short trials. The Pfizer safety analysis [16] pooled 31 trials but the median treatment duration was only 59 days. Long-term safety data is missing. The 2011 web-based monitoring study [12] found that most adverse events (dizziness, somnolence, feeling drunk) appear in the first 14 days and then drop sharply, but that study was not designed to track rare or delayed harms. A 2018 hemodialysis study [18] found dose-dependent increases in falls and fractures, but that population is not the typical NHS patient.

To win a lawsuit you would need to show that the prescriber deviated from a standard of care that the evidence actually supports. The evidence here does not establish that standard clearly. The BMJ review [2] says pregabalin is "moderate" quality evidence for post-herpetic neuralgia and "low" for diabetic neuropathy. A doctor who prescribes it off-label for a condition where the NNT is 11 and the NNH is 5.9 (fibromyalgia) is not obviously negligent, because the guidelines still allow it. The 2019 reclassification [3] changed the prescribing rules but did not change the standard of care.

My call: the evidence does not support a strong negligence claim unless the prescriber ignored a clear contraindication, prescribed a dose far above guidelines, or failed to monitor a known risk like respiratory depression when combined with opioids [9]. Confidence: low. The evidence base is too thin and too conflicted to define what "improper" means in court.